Protein A immunoadsorption combined with rituximab in highly sensitized kidney transplant recipients

Chinese Medical Journal

Volumn 122, Issue 22, 2009, Pages 2752-2756

  Yin, Hang ^a   Hu, Xiao Peng ^a   Li, Xiao Bei ^a   Liu, Hang ^a   Wang, Wei ^a   Ren, Liang ^a   Wang, Yong ^a   Zhang, Xiao Dong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Highly sensitized; Protein A immunoadsorption; Renal transplantation; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PANEL REACTIVE ANTIBODY; PROTEIN A; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; HISTOINCOMPATIBILITY; HLA MATCHING; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATION; SENSITIZATION;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; IMMUNOSORBENT TECHNIQUES; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; STAPHYLOCOCCAL PROTEIN A;

EID: 73449147376     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.22.015     Document Type: Article

References (25)

1. Katzlneson S, Bhaduri S, Cecka JM. Clinical aspects of sensitization. Clin Transpl 1997; 285-296.
2. Jordan SC, Tyan D, Stablein D, McIntosh M, Rose S, Vo A, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256-3262.
3. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346-351.
4. Lorenz M, Regele H, Schillinger M, Kletzmayr J, Haidbauer B, Derfler K, et al. Peritransplant immunoadsorption: a strategy enabling transplantation in highly sensitized crossmatch-positive cadaveric kidney allograft recipients. Transplantation 2005; 79: 696-701.
5. Pescovitz MD, Book BK, Henson S, Leapman SB, Milgrom ML, Kimball J, et al. The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin. Am J Transplant 2003; 3: 497-500.
6. Lederer SR, Friedrich N, Banas B, Welser G, Albert ED, Sitter T. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation. Clin Transplant 2005; 19: 168-174.
7. Jackson AM, Zachary AA. The problem of transplanting the sensitized patient: whose problem is it? Front Biosci 2008; 13: 1396-1412.
8. Lee PC, Terasaki PI, Takemoto SK, Lee PH, Hung CJ, Chen YL, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74: 1192-1194.
9. Michaels PJ, Fishbein MC, Colvin RB. Humoral rejection of human organ transplants. Springer Semin Immunopathol 2003; 25: 119-140.
10. Takemoto SK, Zeevi A, Feng S, Colvin RB, Jordan S, Kobashigawa J, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 1033-1041.
11. Cai J, Terasaki PI. Humoral theory of transplantation: mechanism, prevention, and treatment. Hum Immunol 2005; 66: 334-342.
12. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445.
13. Piro LD, White CA, Grillo-Lopez AJ, Janakiraman N, Saven A, Beck TM, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin?s lymphoma. Ann Oncol 1999; 10: 655-661.
14. Meng HT, Li Y, Liu JH, Xu GX, Teng XD. Post-transplant lymphoproliferative disorder treated with rituximab: case report. Chin Med J 2007; 120: 841-843.
15. Pescovitz MD, Book BK, Henson S, Leapman SB, Milgrom ML, Kimball J, et al. The addition of sirolimus to cyclosporine and steroids inhibits the anti-equine antibody response in renal transplant recipients treated with antithymocyte globulin. Am J Transplant 2003; 3: 497-500.
16. Amante AJ, Ejercito R. Management of highly sensitized patients: capitol medical center experience. Transplant Proc 2008; 40: 2274-2280.
17. Genberg H, Hansson A, Wernerson A, Wennberg L, Tydén G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant 2006; 6: 2418-2428.
18. Matic G, Hofmann D, Winkler R, Tiess M, Michelsen A, Schneidewind JM, et al. Removal of immunoglobulins by a protein A versus an antihuman immunoglobulin G-based system: evaluation of 602 sessions of extracorporeal immunoadsorption. Artif Organs 2000; 24: 103-107.
19. Hu XP, Ma LL, Wang Y, Yin H, Wang W, Yang XY, et al. Rapamycin instead of mycophenolate mofetil or azathioprine in treatment of post-renal transplantation urothelial carcinoma. Chin Med J 2009; 122: 35-38.
20. Toyoda M, Petrosyan A, Pao A, Jordan SC. Immunomodulatory effects of combination of pooled human gammaglobulin and rapamycin on cell proliferation and apoptosis in the mixed lymphocyte reaction. Transplantation 2004; 78: 1134-1138.
21. Smith KG, Isbel NM, Catton MG, Leydon JA, Becker GJ, Walker RG. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998; 13: 160-164.
22. Sun Q, Liu ZH, Yin G, Chen H, Chen J, Ji S, et al. Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients. Nephrol Dial Transplant 2006; 21: 510-517.
23. Zhang XD, Hu XP, Yin H, Wang W, Zhang X, Ma LL, et al. Aspergillus pneumonia in renal transplant recipients. Chin Med J 2008; 121: 791-794.
24. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006; 6: 346-351.
25. Böhmig GA, Exner M, Habicht A, Schillinger M, Lang U, Kletzmayr J, et al. Capillaries C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091-1099.